Juergen Srega - Bruker President
| BRKR Stock | USD 58.38 0.88 1.53% |
President
Mr. Juergen Srega is the President of Bruker CALID Group and Bruker Daltonics Division of the Company. Mr. Srega has served as President of the Bruker CALID Group since January 2013, with responsibility for management of its global operations. Mr. Srega also serves as a Managing Director of Bruker Daltonik GmbH, an indirect whollyowned subsidiary of Bruker located in Germany. Prior to joining us, Mr. Srega served since 1996 in a variety of senior management roles at Thermo Fisher Scientific Inc., a global provider of analytical instruments, equipment, reagents and consumables, software and services for research, analysis, discovery and diagnostics. At Thermo Fisher Scientific, Mr. Srega led a number of significant operating divisions, including as Vice President and General Manager Biomarkers, BRAHMS GmbH, from 2011 to 2012, Vice President and General Manager Scientific Instruments Division Global Products from 2005 to 2011 and Vice President and General Manager Advanced MS from 1996 to 2004. Prior to 1996, Mr. Srega was with Badenwerk AG, a German power utility company located in Karlsruhe, Germany, from 1988 to 1995 and an employee of Bruker GmbH from 1980 to 1988 since 2013.
| Age | 69 |
| Tenure | 11 years |
| Address | 40 Manning Road, Billerica, MA, United States, 01821 |
| Phone | 978 663 3660 |
| Web | https://www.bruker.com |
Juergen Srega Latest Insider Activity
Tracking and analyzing the buying and selling activities of Juergen Srega against Bruker stock is an integral part of due diligence when investing in Bruker. Juergen Srega insider activity provides valuable insight into whether Bruker is net buyers or sellers over its current business cycle. Note, Bruker insiders must abide by specific rules, including filing SEC forms every time they buy or sell Bruker'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Juergen Srega over six months ago Payment of 4840 shares by Juergen Srega of Bruker subject to Rule 16b-3 | ||
Juergen Srega over a year ago Acquisition by Juergen Srega of 14695 shares of Bruker subject to Rule 16b-3 | ||
Juergen Srega over a year ago Acquisition by Juergen Srega of 90000 shares of Bruker subject to Rule 16b-3 |
Bruker Management Efficiency
The company has return on total asset (ROA) of 0.0483 % which means that it generated a profit of $0.0483 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.1973 %, meaning that it created $0.1973 on every $100 dollars invested by stockholders. Bruker's management efficiency ratios could be used to measure how well Bruker manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Bruker's Return On Tangible Assets are relatively stable compared to the past year. As of 11/29/2024, Return On Assets is likely to grow to 0.11, while Return On Capital Employed is likely to drop 0.09. At this time, Bruker's Return On Tangible Assets are relatively stable compared to the past year. As of 11/29/2024, Intangibles To Total Assets is likely to grow to 0.23, while Intangible Assets are likely to drop slightly above 196.5 M.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Stanley Peters | CONMED | 45 | |
| MBAMSHA CHE | Orthopediatrics Corp | 52 | |
| Joseph Flanagan | Integer Holdings Corp | 61 | |
| Alex Thurman | Glaukos Corp | 54 | |
| John Kennedy | CONMED | 66 | |
| Stanley III | CONMED | 49 | |
| Joseph Hauser | Orthopediatrics Corp | 41 | |
| Giovanni Magni | Bio Rad Laboratories | 63 | |
| Payman Khales | Integer Holdings Corp | 54 | |
| Angelo Scopelianos | Axogen Inc | 68 | |
| Gregory Odle | Orthopediatrics Corp | 54 | |
| Keyna Skeffington | LivaNova PLC | 61 | |
| Ronald Hutton | Bio Rad Laboratories | 62 | |
| Tom Thomas | Integer Holdings Corp | 53 | |
| Terence Berge | CONMED | 54 | |
| Peter Shagory | CONMED | 55 | |
| Jim Stephens | Integer Holdings Corp | 50 | |
| Aviva McPherron | Orthofix Medical | N/A | |
| Stephanie Bolton | LivaNova PLC | 42 | |
| Annette Tumolo | Bio Rad Laboratories | 65 | |
| Erick DeVinney | Axogen Inc | 48 | |
Management Performance
| Return On Equity | 0.2 | ||||
| Return On Asset | 0.0483 |
Bruker Leadership Team
Elected by the shareholders, the Bruker's board of directors comprises two types of representatives: Bruker inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Bruker. The board's role is to monitor Bruker's management team and ensure that shareholders' interests are well served. Bruker's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Bruker's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Frank Laukien, Chairman, CEO and Pres | ||
| Burkhard Prause, President and CEO, BEST | ||
| Collin DSilva, Pres Division | ||
| Gerald Herman, Interim CFO, Principal Accounting Officer | ||
| Gerald CPA, Executive CFO | ||
| Juergen Srega, President of Bruker Daltonics Division and President of Bruker Calid Group | ||
| Falko Busse, President of the Bruker BioSpin Group and Executive Officer of the Company | ||
| Urban Faeh, Pres GmbH | ||
| Justin Ward, Senior Development | ||
| Stacey Desrochers, Treasurer Relations | ||
| Mark Munch, President of Bruker Nano Group | ||
| Brent JD, General Secretary |
Bruker Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Bruker a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.2 | ||||
| Return On Asset | 0.0483 | ||||
| Profit Margin | 0.09 % | ||||
| Operating Margin | 0.10 % | ||||
| Current Valuation | 11.12 B | ||||
| Shares Outstanding | 151.6 M | ||||
| Shares Owned By Insiders | 31.91 % | ||||
| Shares Owned By Institutions | 79.71 % | ||||
| Number Of Shares Shorted | 3.01 M | ||||
| Price To Earning | 67.10 X |
Pair Trading with Bruker
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Bruker position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bruker will appreciate offsetting losses from the drop in the long position's value.Moving together with Bruker Stock
Moving against Bruker Stock
| 0.78 | DRUG | Bright Minds Biosciences | PairCorr |
| 0.61 | VANI | Vivani Medical | PairCorr |
| 0.58 | VCYT | Veracyte | PairCorr |
| 0.55 | VCEL | Vericel Corp Ord | PairCorr |
| 0.5 | VERA | Vera Therapeutics | PairCorr |
The ability to find closely correlated positions to Bruker could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Bruker when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Bruker - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Bruker to buy it.
The correlation of Bruker is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Bruker moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Bruker moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Bruker can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Bruker Stock Analysis
When running Bruker's price analysis, check to measure Bruker's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bruker is operating at the current time. Most of Bruker's value examination focuses on studying past and present price action to predict the probability of Bruker's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bruker's price. Additionally, you may evaluate how the addition of Bruker to your portfolios can decrease your overall portfolio volatility.